Sanofi is buying an immunology drug from Dren Bio, Inc. for up to $1.9 billion, in a deal it said will help it become a ...

Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.

Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to ...

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...

French pharma major Sanofi (Euronext: SAN) today revealed it has entered into a definitive agreement with privately-held US biotech Dren Bio, to acquire the latter’s DR-0201, a targeted bispecific ...

Sanofi adopts US FDA-selected flu strains to ensure readiness for the 2025-26 flu season: Bridgewater, New Jersey Monday, March 17, 2025, 14:00 Hrs [IST] Sanofi announced the imme ...

Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...

Sanofi (NASDAQ:SNY) has struck a major deal to acquire Dren Bios autoimmune disease treatment, DR-0201, reinforcing its ...

Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid ...

Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025 ...